265 related articles for article (PubMed ID: 34097244)
1. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
[TBL] [Abstract][Full Text] [Related]
2. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
Barrett A; Boye KS; García-Pérez LE; Giorgino F; Guerci B; Füchtenbusch M; Yu M; Sapin H; Dib A; Heitmann E; Federici MO; Lebrec J
J Med Econ; 2024; 27(1):866-879. PubMed ID: 38963346
[TBL] [Abstract][Full Text] [Related]
3. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Guerci B; Giorgino F; Sapin H; Boye K; Lebrec J; Federici MO; Heitmann E; Dib A; Füchtenbusch M; García-Pérez LE
Diabetes Obes Metab; 2022 Dec; 24(12):2373-2382. PubMed ID: 35876235
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
5. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS; Lebrec J; Dib A; Heitmann E; Federici MO; Yu M; Sapin H; Barrett A; Guerci B; Giorgino F; Füchtenbusch M; García-Pérez LE
Diabetes Obes Metab; 2023 Dec; 25(12):3453-3464. PubMed ID: 37712754
[TBL] [Abstract][Full Text] [Related]
6. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Giorgino F; Guerci B; Füchtenbusch M; Lebrec J; Boye K; Orsini Federici M; Heitmann E; Dib A; Yu M; Sapin H; García-Pérez LE
Diabetes Obes Metab; 2023 Dec; 25(12):3465-3477. PubMed ID: 37700627
[TBL] [Abstract][Full Text] [Related]
7. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
Boye KS; Sapin H; García-Pérez LE; Rosilio M; Orsini Federici M; Heitmann E; Jung H; Aigner U; Guerci B; Giorgino F; Norrbacka K
Diabetes Ther; 2020 Oct; 11(10):2383-2399. PubMed ID: 32880876
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
[TBL] [Abstract][Full Text] [Related]
11. Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).
Guo L; Li L; Yu Q; Wang N; Chen J; Wang Z; Ding Y
Diabetes Ther; 2022 Jun; 13(6):1231-1244. PubMed ID: 35583797
[TBL] [Abstract][Full Text] [Related]
12. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
[TBL] [Abstract][Full Text] [Related]
13. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
[TBL] [Abstract][Full Text] [Related]
14. Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.
Brown RE; Abitbol A; Bajaj HS; Goldenberg R; Khandwala H; Abdel-Salam S; Aronson R
Diabetes Res Clin Pract; 2019 Oct; 156():107820. PubMed ID: 31446111
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.
Ghosal S; Sinha B
Clin Diabetes Endocrinol; 2018; 4():11. PubMed ID: 29760945
[TBL] [Abstract][Full Text] [Related]
16. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
[TBL] [Abstract][Full Text] [Related]
17. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
[TBL] [Abstract][Full Text] [Related]
18. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
[TBL] [Abstract][Full Text] [Related]
19. Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.
Hoog M; Paczkowski R; Huang A; Halpern R; Buysman E; Stackland S; Zhang Y; Wangia-Dixon R
Diabetes Ther; 2023 Nov; 14(11):1947-1958. PubMed ID: 37740872
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
Robinson S; Boye KS; Mody R; Strizek AA; Konig M; Malik RE; Kennedy-Martin T
Diabetes Ther; 2020 Jul; 11(7):1437-1466. PubMed ID: 32524494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
